Lymphocyte populations and their change during five-year
glatiramer acetate treatment

J 2018

Lymphocyte populations and their change during five-year glatiramer acetate treatment

PAVELEK, Zbyšek, Oldřich VYŠATA, Lukáš SOBÍŠEK, Blanka KLÍMOVA, Ctirad ANDRÝS et. al.

Basic information

Original name

Lymphocyte populations and their change during five-year glatiramer acetate treatment

Authors

PAVELEK, Zbyšek (203 Czech Republic, guarantor), Oldřich VYŠATA, Lukáš SOBÍŠEK (203 Czech Republic), Blanka KLÍMOVA (203 Czech Republic), Ctirad ANDRÝS (203 Czech Republic), Doris VOKURKOVÁ (203 Czech Republic), Radka MAZUROVÁ, Pavel ŠTOURAČ (203 Czech Republic, belonging to the institution) and Martin VALIŠ (203 Czech Republic)

Edition

Neurologia i Neurochirurgia Polska, Poznan, Termedia Publishing House LTD, 2018, 0028-3843

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30210 Clinical neurology

Country of publisher

Poland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.006

RIV identification code

RIV/00216224:14110/18:00104209

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.pjnns.2018.08.001

UT WoS

000446401500007

Keywords in English

Multiple sclerosis; Lymphocytes; Glatiramer acetate; Parameters; Treatment

Abstract

V originále

Background: The goal of this study was to determine the characteristics that are affected in patients treated with glatiramer acetate (GA). Methods: A total of 113 patients were included in this study. Patients were treated with glatiramer acetate (subcutaneous injection, 20 mg, each day). Peripheral blood samples were obtained just prior to treatment as well as 5 years after GA treatment. All the calculations were performed with the statistical system R (r-project.org). Results: After 5 years of treatment, a significant decrease was found in the absolute and relative CD3+/CD69+ counts, the absolute and relative CD69 counts, the relative CD8+/CD38+ count and the relative CD38 count. A significant increase was found in the absolute and relative CD5+/CD45RA+ counts and the absolute CD5+/CD45RO+ count after 5 years of treatment. Conclusion: This study presents some parameters that were affected by long-term GA treatment. (C) 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.

Citovat

PAVELEK, Zbyšek, Oldřich VYŠATA, Lukáš SOBÍŠEK, Blanka KLÍMOVA, Ctirad ANDRÝS, Doris VOKURKOVÁ, Radka MAZUROVÁ, Pavel ŠTOURAČ and Martin VALIŠ. Lymphocyte populations and their change during five-year glatiramer acetate treatment. Neurologia i Neurochirurgia Polska. Poznan: Termedia Publishing House LTD, 2018, vol. 52, No 5, p. 587-592. ISSN 0028-3843. Available from: https://dx.doi.org/10.1016/j.pjnns.2018.08.001.

@article{1455737,
   author = {Pavelek, Zbyšek and Vyšata, Oldřich and Sobíšek, Lukáš and Klímova, Blanka and Andrýs, Ctirad and Vokurková, Doris and Mazurová, Radka and Štourač, Pavel and Vališ, Martin},
   article_location = {Poznan},
   article_number = {5},
   doi = {http://dx.doi.org/10.1016/j.pjnns.2018.08.001},
   keywords = {Multiple sclerosis; Lymphocytes; Glatiramer acetate; Parameters; Treatment},
   language = {eng},
   issn = {0028-3843},
   journal = {Neurologia i Neurochirurgia Polska},
   title = {Lymphocyte populations and their change during five-year glatiramer acetate treatment},
   volume = {52},
   year = {2018}
}

TY  - JOUR
ID  - 1455737
AU  - Pavelek, Zbyšek - Vyšata, Oldřich - Sobíšek, Lukáš - Klímova, Blanka - Andrýs, Ctirad - Vokurková, Doris - Mazurová, Radka - Štourač, Pavel - Vališ, Martin
PY  - 2018
TI  - Lymphocyte populations and their change during five-year glatiramer acetate treatment
JF  - Neurologia i Neurochirurgia Polska
VL  - 52
IS  - 5
SP  - 587-592
EP  - 587-592
PB  - Termedia Publishing House LTD
SN  - 00283843
KW  - Multiple sclerosis
KW  - Lymphocytes
KW  - Glatiramer acetate
KW  - Parameters
KW  - Treatment
N2  - Background: The goal of this study was to determine the characteristics that are affected in patients treated with glatiramer acetate (GA). Methods: A total of 113 patients were included in this study. Patients were treated with glatiramer acetate (subcutaneous injection, 20 mg, each day). Peripheral blood samples were obtained just prior to treatment as well as 5 years after GA treatment. All the calculations were performed with the statistical system R (r-project.org). Results: After 5 years of treatment, a significant decrease was found in the absolute and relative CD3+/CD69+ counts, the absolute and relative CD69 counts, the relative CD8+/CD38+ count and the relative CD38 count. A significant increase was found in the absolute and relative CD5+/CD45RA+ counts and the absolute CD5+/CD45RO+ count after 5 years of treatment. Conclusion: This study presents some parameters that were affected by long-term GA treatment. (C) 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
ER  -

PAVELEK, Zbyšek, Oldřich VYŠATA, Lukáš SOBÍŠEK, Blanka KLÍMOVA, Ctirad ANDRÝS, Doris VOKURKOVÁ, Radka MAZUROVÁ, Pavel ŠTOURAČ and Martin VALIŠ. Lymphocyte populations and their change during five-year glatiramer acetate treatment. \textit{Neurologia i Neurochirurgia Polska}. Poznan: Termedia Publishing House LTD, 2018, vol.~52, No~5, p.~587-592. ISSN~0028-3843. Available from: https://dx.doi.org/10.1016/j.pjnns.2018.08.001.

Detailed Information on Publication Record